ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $7.50.

PRQR has been the subject of several research analyst reports. Weiss Ratings raised shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. JonesTrading reduced their price target on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Bank of America started coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They set a “buy” rating and a $8.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating on shares of ProQR Therapeutics in a research report on Monday, August 17th.

Insider Buying and Selling at ProQR Therapeutics

In other news, Director Bart Filius purchased 150,000 shares of the stock in a transaction dated Friday, July 17th. The stock was acquired at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the transaction, the director directly owned 300,000 shares in the company, valued at approximately $516,000. This represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel de Boer acquired 150,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was purchased at an average cost of $1.74 per share, with a total value of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. This represents a 100.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have bought 450,000 shares of company stock valued at $757,500. Company insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors have recently bought and sold shares of PRQR. RFG Advisory LLC increased its holdings in ProQR Therapeutics by 236.8% during the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 45,000 shares during the period. Axiom Investment Management LLC purchased a new position in shares of ProQR Therapeutics in the 1st quarter valued at about $53,000. Walleye Capital LLC boosted its stake in shares of ProQR Therapeutics by 2.7% in the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after buying an additional 15,744 shares during the period. Finally, Bank of America Corp DE boosted its stake in shares of ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after buying an additional 11,186 shares during the period. 32.65% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $1.65 on Wednesday. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $3.10. The business’s fifty day simple moving average is $1.94 and its 200-day simple moving average is $1.76. The firm has a market cap of $173.85 million, a PE ratio of -3.59 and a beta of 0.06.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $4.56 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%. As a group, equities analysts expect that ProQR Therapeutics will post -0.45 earnings per share for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. (NASDAQ: PRQR) is a biotechnology company focused on developing RNA-based medicines for genetic and other serious diseases. The company’s research platform is designed to modify RNA and potentially correct disease-causing genetic defects without permanently changing a patient’s DNA.

ProQR has primarily pursued treatments for inherited retinal disorders and other conditions affecting the eye. Its pipeline has included investigational RNA therapies such as sepofarsen, developed for Leber congenital amaurosis type 10, and ultevursen, developed for Usher syndrome type 2A.